Clinical Trials Logo

Antipsychotics clinical trials

View clinical trials related to Antipsychotics.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03376763 Completed - Schizophrenia Clinical Trials

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

MAESTRO
Start date: November 21, 2017
Phase: Phase 4
Study type: Interventional

Interventional, multicenter, open-label, 20 weeks study - To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena. - To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

NCT ID: NCT01562808 Completed - Cognition Clinical Trials

Change in Brain Metabolism and Cognitive Function by Aripiprazole

Start date: January 2009
Phase: N/A
Study type: Interventional

Dopamine receptor occupancy and brain metabolism were measured using positron emission tomography after the administration of aripiprazole. Working memory performance was also measured using N-back task. The investigators explored the relationship between changes in brain metabolism and working memory performance.

NCT ID: NCT00937755 Completed - Schizophrenia Clinical Trials

The Study of Atypical Antipsychotics-induced Metabolic Disturbances

Start date: March 2006
Phase: Phase 4
Study type: Observational

Schizophrenia is one of the most severe mental illnesses. The antipsychotic drugs, introduced in early 1950s, have revolutionized the treatment of schizophrenia. About 2 to 4 times as many patients relapse when treated with a placebo as do those treated with antipsychotic drugs. For these medications to be maximally beneficial, they must have an acceptable side effect profile and be taken as prescribed. One untoward effect of many antipsychotic drugs is weight gain. The extent of weight gain apparently varies by drug, which may be because of drugs'differing degrees of action on serotonergic, dopaminergic, histaminergic, and other neurotransmitter systems. Obesity is a threat to health and longevity. Weight gain may also cause patients taking antipsychotic medication to discontinue their medication, which may predispose them to relapse. The pattern of weight gain and metabolic disturbance may vary between the different antipsychotic agents. The underlying mechanism and treatment of these adverse metabolic effects remain unclear. This study will recruit 60 schizophrenic patients during. The patients received monotherapy with atypical antipsychotics (olanzapine, quetiapine, or risperidone). The assessment of metabolic profile will be monitored at baseline, week 2, week 4, and week 8. The measurements include anthropometrical parameters, body composition, glucose level, insulin level, lipid profile, and leptin level. Intra-venous glucose tolerance test will be used to assess the insulin secretion and insulin sensitivity. This proposal broadly aims to discover the underlying mechanism of antipsychotics induced metabolic disturbance and develop efficient treatment to correct it.